These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16395110)

  • 21. Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.
    Rose WE
    J Am Pharm Assoc (2003); 2014; 54(2):198-201. PubMed ID: 24632933
    [No Abstract]   [Full Text] [Related]  

  • 22. Epidemiology and meningococcal serogroup distribution in the United States.
    Hershey JH; Hitchcock W
    Clin Pediatr (Phila); 2010 Jun; 49(6):519-24. PubMed ID: 20507868
    [No Abstract]   [Full Text] [Related]  

  • 23. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018.
    Knol MJ; Ruijs WL; Antonise-Kamp L; de Melker HE; van der Ende A
    Euro Surveill; 2018 Apr; 23(16):. PubMed ID: 29692317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
    Pace D
    Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.
    Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA
    Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine.
    Salleras L; Domínguez A; Cardeñosa N
    Vaccine; 2003 Jan; 21(7-8):729-33. PubMed ID: 12531350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods.
    Monalisa Mendes Dantas Sales N; Azevedo J; Teles Bastos Ribeiro M; Fonseca de Freitas H; Pedreira da Silva Filho H; Machado Cordeiro S; Galvão Reis M; Neves Reis J
    Vaccine; 2020 Sep; 38(40):6267-6273. PubMed ID: 32741673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global practices of meningococcal vaccine use and impact on invasive disease.
    Ali A; Jafri RZ; Messonnier N; Tevi-Benissan C; Durrheim D; Eskola J; Fermon F; Klugman KP; Ramsay M; Sow S; Zhujun S; Bhutta Z; Abramson J
    Pathog Glob Health; 2014 Jan; 108(1):11-20. PubMed ID: 24548156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
    Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
    Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination campaign against meningococcal disease in army recruits in Italy.
    Stroffolini T
    Epidemiol Infect; 1990 Dec; 105(3):579-83. PubMed ID: 2249722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for vaccine prevention of meningococcal infection.
    Harrison LH
    Clin Microbiol Rev; 2006 Jan; 19(1):142-64. PubMed ID: 16418528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil.
    Cardoso CW; Pinto LL; Reis MG; Flannery B; Reis JN
    Vaccine; 2012 Aug; 30(37):5541-6. PubMed ID: 22749604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.